While the capital raise strengthens Celldex’s balance sheet for clinical development, the lack of near-term catalysts or data readouts suggests limited immediate upside. Traders should monitor pipeline advancement and future dilution risk given the company's pre-revenue status.
Price Chart
Executive Summary
Celldex Therapeutics closed an underwritten public offering of 11.9 million shares at $29.00 per share, raising approximately $345 million in gross proceeds. The capital will support the company's clinical-stage biotech pipeline focused on mast cell biology and immune system therapeutics.
Key Financial Metrics
Key Facts
- Celldex closed a public offering of 11,896,750 common shares, including full exercise of the underwriters' option for 1,551,750 additional shares.
- Offering price was $29.00 per share, resulting in gross proceeds of approximately $345 million.
- Proceeds will be used for general corporate purposes, including advancing Celldex’s clinical-stage pipeline in inflammatory, allergic, and autoimmune diseases.
- Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor acted as joint bookrunners; LifeSci Capital and H.C. Wainwright as co-lead managers.
- The offering was made under an effective shelf registration (Form S-3, File No. 333-275300) and completed via prospectus supplement.
Financial Impact
$345 million in gross proceeds, with no immediate dilution impact factored into stock price post-offering
Risk Factors
- Dilution from the issuance of new shares could pressure stock price despite strong gross proceeds.
- As a clinical-stage biotech with no commercial products, Celldex remains highly dependent on trial outcomes and future funding rounds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268530 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▼ −19.96% | ▼ −20.71% | $32.07 (+0.16%) |
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▲ +19.96% | ▲ +20.71% | $32.07 (−0.16%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $32.07 (+7.04%) |
Jun 10, 2026 16w ago | Press Release | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $32.07 (+7.04%) |
May 7, 2026 21w ago | 8-K | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $32.07 (−5.59%) |
May 7, 2026 21w ago | Press Release | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $32.07 (−5.59%) |
Apr 6, 2026 25w ago | Press Release | $31.37 $32.77 | ▲ +4.46% | ▼ −4.52% | $32.07 (+2.23%) |
Apr 2, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
Apr 1, 2026 26w ago | 424B5 | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
Apr 1, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access